Servier joins AdBIOPRO as new partner
AdBIOPRO Competence Center for Advanced Bioprocessing partners with Servier for advancing knowledge to improve sustainability and performance in manufacturing of therapeutic antibodies.
STOCKHOLM and PARIS, August 28, 2024 -- Servier joins AdBIOPRO Competence Centre, as partner in a key project of the competence development consortium. Servier brings expertise in batch processes and Process Analytical Technologies applicable to deepen knowledge of continuous bioprocessing for therapeutic antibodies production. AdBIOPRO offers an excellent platform of cutting-edge technologies and dynamic industry-academia collaboration to realize this. Focus will be on understanding what continuous bioprocessing can bring in terms of performance and sustainability in comparison with traditional batch processing. Professor Véronique Chotteau, Director of AdBIOPRO stated, “It is a real pleasure to welcome Servier as new partners to the Competence Center. Their focus and aspiration are completely in line with our objectives and complete admirably AdBIOPRO Consortium.”
About Servier
Servier is a global pharmaceutical group governed by a Foundation that aspires to have a meaningful social impact, both for patients and for a sustainable world. With its unique governance model, it can fully serve its vocation with a long-term vision of being committed to therapeutic progress to serve patient needs. The 21,900 employees of the Group are daily inspired by this shared vocation.
A world leader in cardiology, Servier’s ambition is to become a focused and innovative player in oncology by targeting rare cancers: the Group allocates over 70% of its R&D budget to developing targeted and innovative therapies in oncology. In neuroscience and immuno-inflammatory Servier is focused on a limited number of diseases in which accurate patient profiling allows to offer a targeted therapeutic response through precision medicine.
To promote access to quality care for all at a lower cost, the Group also offers a range of quality generic drugs covering many pathologies, relying on strong brands in France, Eastern Europe, Brazil and Nigeria.
In all these areas, the Group includes the patient voice at each stage of the life cycle of a medicine.
Headquartered in France, Servier relies on a strong geographical footprint in over 150 countries and achieved a revenue of €5.3 billion in 2023.
About AdBIOPRO
AdBIOPRO, The Competence Centre for Advanced BioProduction, provides a dynamic hub for world-leading knowledge and technology development for manufacturing of therapeutic antibodies, glycoproteins, and cell and gene therapy products (ATMPs). We focus on intensifying or enabling the production of these biologics. The paradigm shift towards next generation bioproduction by continuous processes takes a large place in making biologics production more efficient, sustainable and safe. AdBIOPRO is funded by VINNOVA, Sweden´s Innovation Agency, and the collaborating industrial and academic partners of the Competence Centre.
AdBIOPRO is driven by the complementary expertise of seven teams at KTH, Lund University, the Karolinska Cell Therapy Centre (KCC) at Karolinska University Hospital, Karolinska Institutet and Linköping University together with sixteen industrial partners; Alfa Laval, ArgusEye, AstraZeneca, BioInvent International, BioLamina, Cellcolabs, Cellevate, Cytiva, Breez Biosystems, a company of Merck KGaA Darmstadt Germany, Magic Bioprocessing, Metenova, a company of Repligen, NorthX Biologics, Nyctea Technologies, Servier, TimeGate Instruments and Valneva, all companies with cutting edge expertise in their respective areas.
The academic expertise constellation with world-leading and recognized competence in their respective fields, covers mammalian/human cell bioprocessing, cell omics characterization, gene therapy, immune cell therapy, GMP manufacturing for cell therapy, downstream processing, sensor technology, as well as mathematic modelling, process optimization and control. In particular, Chotteau’s and Nilsson's groups at KTH and Lund University are international leaders for continuous cell culture and continuous purification respectively, and their combined competence in AdBIOPRO is unique on a global perspective. The KCC lead by Blomberg has a track record of ≥ 40 GMP productions of ATMPs used for human therapeutic trials.